Modelling HDV kinetics under the entry inhibitor bulevirtide suggests the existence of two HDV-infected cell populations

Modelling HDV kinetics under the entry inhibitor bulevirtide suggests the existence of two HDV-infected cell populations

Background & Aims: Bulevirtide (BLV) was approved for the treatment of compensated chronic hepatitis D virus (HDV) infection in Europe in 2020. However, research into the effects of the entry inhibitor BLV on HDV-host dynamics is in its infancy. Methods: Eighteen patients with HDV under nucl...

Full description

Bibliographic Details
Main Authors: Louis Shekhtman, Scott J. Cotler, Elisabetta Degasperi, Maria Paola Anolli, Sara Colonia Uceda Renteria, Dana Sambarino, Marta Borghi, Riccardo Perbellini, Floriana Facchetti, Ferruccio Ceriotti, Pietro Lampertico, Harel Dahari
Format: Article
Language:English
Published: Elsevier 2024-02-01
Series:JHEP Reports
Subjects:
HDV RNA
Bulevirtide
mathematical modeling
HBsAg
ALT
Online Access:http://www.sciencedirect.com/science/article/pii/S2589555923002975

Similar Items

Similar Items